Choosing Immunotherapy
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.
Video Categories: 2018 AONN Midyear, Immunotherapy, and Video LibraryVideo Library
Reimbursement Challenges and Solutions with Molecular Biomarker Testing
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Financial Constraints to Molecular Biomarker Testing
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Best Practices in Oncology Biomarker Testing
Drs. Goeffrey Oxnard and Lauren Ritterhouse review the best practices to improve efficiencies in biomarker testing, including effective communication among the healthcare team, the pathologist, and the patient, as well as expediting processing in the pathology laboratory.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Creating a Paradigm for Biomarker Testing
Drs. Goeffrey Oxnard and Lauren Ritterhouse consider the advantages and disadvantages of liquid biopsies as an early screening tool for biomarker testing, and how to integrate various approaches into a biomarker testing paradigm.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
The Role of Tumor Mutational Burden in Lung Cancer
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Improving Efficiencies in Oncology Biomarker Testing
Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Dealing with Issues of Obtaining Sufficient Tissue in Performing Biomarker Testing
Drs. Roy Herbst and David Rimm review some of the problems associated with obtaining enough tissue to perform biomarker testing, the need to triage tissue to ensure that standard of care tests are completed, and the potential role of liquid biopsies
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Genetic vs Genomic Testing: What’s the Difference?
Dr Andrey Antov provides a useful metaphor to explain how genetic testing and genomic testing differ from one another and the purpose behind each type of testing.
Video Categories: 2018 AONN Midyear and Video Library